Literature DB >> 15887411

[Clinico-pathology and differential diagnosis of Binswanger's disease].

Tibor Kovács1, Imre Szirmai, Mátyás Papp.   

Abstract

Pathologically, Binswanger's disease is subcortical periventricular leucoencephalopathy sparing the U fibers. Clinically it is characterised by executive dysfunction, gait problems, urinary incontinence, pseudobulbar palsy, mood disturbances and dementia. The pathomechanism of Binswanger's disease is unclear. It is hypothesized that it results from an ischemic-hypoxic injury of the periventricular white matter, which, in turn, can be caused by a sclerotic elongation of the medullary arteries, widening of the perivascular spaces or decreased brain perfusion due to hypotension or heart disease. The symptoms of Binswanger's disease frequently overlap with those of normal pressure hydrocephalus, vascular parkinsonism and Alzheimer's disease. A diagnostic criterion of Binswanger's disease is radiologically demonstrated leukoaraiosis, which, on the other hand, is not equivalent with Binswanger's disease. A good clinical response after lumbar puncture or shunt implantation might lead to confusion with normal pressure hydrocephalus, which further complicates the clinical diagnosis. It is likely that among the above mentioned disorders there are a number of transitional forms and overlaps, which might be explained by the common pathomechanism of disturbance in cerebrospinal fluid circulation.

Entities:  

Mesh:

Year:  2005        PMID: 15887411

Source DB:  PubMed          Journal:  Ideggyogy Sz        ISSN: 0019-1442            Impact factor:   0.427


  2 in total

1.  Structural remodeling secondary to functional remodeling in advanced-stage peripheral facial neuritis.

Authors:  Jie Ma; Xu-Yun Hua; Mou-Xiong Zheng; Jia-Jia Wu; Bei-Bei Huo; Xiang-Xin Xing; Wei Ding; Jian-Guang Xu
Journal:  Neurol Sci       Date:  2020-03-23       Impact factor: 3.307

2.  Biomarkers in chronic adult hydrocephalus.

Authors:  Andrew Tarnaris; Laurence D Watkins; Neil D Kitchen
Journal:  Cerebrospinal Fluid Res       Date:  2006-10-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.